MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Johnson and Johnson

Open

BrancheGesundheitswesen

153.39 -0.62

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

152.41

Max

155.08

Schlüsselkennzahlen

By Trading Economics

Einkommen

3.4B

Verkäufe

20M

23B

KGV

Branchendurchschnitt

17.455

57.333

EPS

2.77

Dividendenrendite

3.3

Gewinnspanne

15.235

Angestellte

138,100

EBITDA

652M

5.9B

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+9.18% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

3.30%

2.63%

Nächstes Ergebnis

16. Juli 2025

Nächste Dividendenausschüttung

10. Juni 2025

Nächstes Ex-Dividendendatum

27. Mai 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

11B

378B

Vorheriger Eröffnungskurs

154.01

Vorheriger Schlusskurs

153.39

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Johnson and Johnson Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

15. Apr. 2025, 15:12 UTC

Ergebnisse

J&J Boosts Outlook Despite Incoming Tariff Costs -- Update

15. Apr. 2025, 10:35 UTC

Top News
Ergebnisse

J&J Increases Outlook After Beating 1Q Expectations

18. Apr. 2025, 11:00 UTC

Top News

Johnson & Johnson Pivots Its AI Strategy -- WSJ

17. Apr. 2025, 20:34 UTC

Ergebnisse

UnitedHealth Woes Aren't Dragging Down the Entire Sector. Here's Why. -- Barrons.com

17. Apr. 2025, 18:24 UTC

Ergebnisse

UnitedHealth Woes Aren't Dragging Down the Entire Sector. Here's Why. -- Barrons.com

15. Apr. 2025, 19:06 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Bank of America, Citigroup, Netflix, Boeing, Tesla, HPE, Applied Digital, and More -- Barrons.com

15. Apr. 2025, 18:52 UTC

Market Talk
Ergebnisse

J&J's 1Q Performance Signals Positive Outlook for MedTech Sector -- Market Talk

15. Apr. 2025, 14:54 UTC

Ergebnisse

Why Johnson & Johnson Stock Is Down After Earnings Beat Expectations -- Barrons.com

15. Apr. 2025, 13:19 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Why Johnson & Johnson Stock Is Down After Earnings Beat Expectations -- Barrons.com

15. Apr. 2025, 11:52 UTC

Ergebnisse

Johnson & Johnson Tops Earnings Estimates and Boosts Outlook. The Stock Slips. -- Barrons.com

15. Apr. 2025, 11:14 UTC

Ergebnisse

Johnson & Johnson Tops Earnings Estimates and Boosts Outlook. The Stock Slips. -- Barrons.com

15. Apr. 2025, 10:51 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Boeing, Tesla, Bank of America, J&J, Netflix, Allegro MicroSystems, and More -- Barrons.com

15. Apr. 2025, 10:37 UTC

Top News
Ergebnisse

Johnson & Johnson Tops Earnings Estimates and Boosts Outlook. The Stock Rises. -- Barrons.com

15. Apr. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson Now Sees 2025 Operational Sales of $91.6B-$92.4B Vs. Prior Outlook $90.9B-$91.7B >JNJ

15. Apr. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson Backs 2025 Adj EPS $10.50-Adj EPS $10.70 >JNJ

15. Apr. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson Raises 2025 View To Sales $91B-$91.8B Vs Prior View $89.2B-$90B >JNJ

15. Apr. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson Now Sees 2025 Adjusted Operational EPS $10.50-$10.70 Vs Prior View $10.75-$10.95 >JNJ

15. Apr. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson: Including Tariff Costs, Dilution From Intra-Cellular Therapies Buy and Updated Forex, Maintain FY Adj EPS Outlook of 6.2% Growth at Mid-Point >JNJ

15. Apr. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson: Strong 1Q Operational Sales Growth Reinforces Our Confidence in 2025 Guidance >JNJ

15. Apr. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson 1Q Sales $21.89B >JNJ

15. Apr. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson: Increasing FY25 Operational Sales Guidance to Reflect Addition of Caplyta Following Completion of Intra-Cellular Therapies Acquisition >JNJ

15. Apr. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson 1Q Worldwide MedTech Sales $8.02B >JNJ

15. Apr. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson 1Q International Sales $9.59B >JNJ

15. Apr. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson 1Q Adj EPS $2.77 >JNJ

15. Apr. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson 1Q Orthopaedics Sales $2.24B >JNJ

15. Apr. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson: MedTech 1Q Operational Sales Growth Driven Primarily by Abiomed and Wound Closure Products, Partially Offset by Spine, Sports & Other >JNJ

15. Apr. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson Still Sees 2025 Adjusted Operational Sales Growth of 2.0%-3.0% >JNJ

15. Apr. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson: Innovative Medicine 1Q Sales Growth Driven in Part by Higher Sales of Darzalex and Spravato, Partially Offset by Falling Sales of Stelara >JNJ

15. Apr. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson 1Q U.S. Sales $12.31B >JNJ

15. Apr. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson 1Q EPS $4.54 >JNJ

Peer-Vergleich

Kursveränderung

Johnson and Johnson Prognose

Kursziel

By TipRanks

9.18% Vorteil

12-Monats-Prognose

Durchschnitt 169.15 USD  9.18%

Hoch 185 USD

Tief 159 USD

Basierend auf 14 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Johnson and Johnson – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

14 ratings

7

Buy

7

Halten

0

Sell

Technischer Score

By Trading Central

154.36 / 157.47Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Bearish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.